サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1800739

ヒトマイクロバイオームの世界市場：製品別、タイプ別、疾患別、投与経路別、サービス別、エンドユーザー別、地域別 - 2031年までの予測

Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics, Diagnostics), Disease (Infectious, Gastrointestinal), Route (Oral, Rectal), CDMO (Formulation, Strain Engineering), Type (BCT/FMT, Live Bacteria) - Global Forecast to 2031

出版日
ページ情報
英文 371 Pages
納期
即納可能 即納可能とは
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.25円
ヒトマイクロバイオームの世界市場：製品別、タイプ別、疾患別、投与経路別、サービス別、エンドユーザー別、地域別 - 2031年までの予測
出版日: 2025年08月20日
発行: MarketsandMarkets
ページ情報: 英文 371 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ヒトマイクロバイオームの市場規模は、予測期間中に31.0%のCAGRで拡大し、2024年の14億米ドルから2031年には70億9,000万米ドルに達すると予測されています。

調査範囲
調査対象年 2024年～2031年
基準年 2024年
予測期間 2025年～2031年
検討単位 金額（10億米ドル）
セグメント 製品別、タイプ別、疾患別、投与経路別、サービス別、エンドユーザー別、地域別
対象地域 北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカ

マイクロバイオーム研究のためのマイクロバイオーム産業と学界の協力体制や個別化医療に対する需要の高まりなどの要因が、ヒトマイクロバイオーム市場の成長を促進しています。しかし、複雑な規制政策がマイクロバイオームの商業化に悪影響を及ぼし、市場の成長を抑制しています。

2024年のヒトマイクロバイオームサプリメント分野では、プロバイオティクス分野が最大のシェアを占めています。

Human Microbiome Market-IMG1

市場はヒトマイクロバイオーム医薬品、ヒトマイクロバイオームサプリメント、ヒトマイクロバイオーム診断に区分されます。ヒトマイクロバイオームサプリメントは、プロバイオティクス、プレバイオティクス、シンバイオティクスの3つの主要製品で分析されます。2024年のヒト・マイクロバイオーム市場で最大のシェアを占めるセグメントはプロバイオティクスです。この優位性は、プロバイオティクスの広範な使用、消費者の強い認知、市販の健康・ウェルネス製品における確立された存在感によるものです。プロバイオティクスは、消化器系の健康をサポートし、免疫力を高め、腸内微生物のバランスを維持するために一般的に使用されており、予防ヘルスケアの日常的な一部となっています。プロバイオティクスはカプセル、粉末、飲食品、機能性食品など様々な形態で販売されており、入手しやすく消費者の支持を集めています。さらに、多くの臨床研究が特定のプロバイオティクス株の有効性を裏付けており、消費者とヘルスケア・プロバイダーの信頼性を高めています。プロバイオティクスをプレバイオティクスやビタミンなどの他の生物活性物質と組み合わせることができるため、さまざまな層でプロバイオティクスの魅力がさらに拡大しています。これらの要因が相まって、プロバイオティクスはヒト・マイクロバイオーム・サプリメント分野の主要製品タイプとなっています。

ヒトマイクロバイオーム市場は、消化器疾患、感染症、内分泌・代謝疾患、その他の疾患に区分されます。2024年には、消化器疾患分野が市場で最大のシェアを占めました。この背景には、腸内細菌叢と過敏性腸症候群（IBS）、炎症性腸疾患（IBD）、潰瘍性大腸炎、クローン病などの疾患との強い関連があります。これらの慢性疾患は世界的に有病率が高く、長期的な管理が必要な場合が多いため、腸内細菌叢を標的とした代替療法や補助療法の需要が生じています。

消化器疾患の開発と進行における微生物の不均衡の役割を支持する研究が増えており、マイクロバイオームベースの診断と治療への投資の増加を促しています。IBDとIBSをターゲットとした臨床段階の製品がいくつか開発中であり、科学的関心と満たされていない患者ニーズを反映しています。プロバイオティクスやシンバイオティクスなど、消化器系の健康を目的としたマイクロバイオームのサプリメントが利用可能になったことで、消費者のアクセスはさらに拡大し、この分野の市場成長に寄与しています。

2024年、北米はヒトマイクロバイオーム市場で最大のシェアを占めました。この背景には、主要市場参入企業の存在感の強さ、先進的なヘルスケアインフラ、マイクロバイオーム研究開発への投資の多さなど、いくつかの要因があります。この地域では、特に米国において、マイクロバイオーム科学に焦点を当てた数多くの臨床試験や学術共同研究が行われています。また、米国FDAがVOWSTやRebyotaといったマイクロバイオームベースの治療薬を初めて承認し、重要な規制上の先例となるなど、規制上の支援も市場成長に寄与しています。さらに北米では、腸の健康と予防的ウェルネスに対する意識の高まりにより、マイクロバイオーム・サプリメント、特にプロバイオティクスとシンバイオティクスの消費者基盤が大きく成長しています。高いヘルスケア支出、慢性疾患の有病率の増加、有利な償還政策は、世界のヒトマイクロバイオーム市場における北米の主導的地位をさらに強固なものにしています。

当レポートでは、世界のヒトマイクロバイオーム市場について調査し、製品別、タイプ別、疾患別、投与経路別、サービス別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
  • 顧客ビジネスに影響を与える動向/混乱
  • 価格分析
  • バリューチェーン分析
  • エコシステム分析
  • 投資と資金調達のシナリオ
  • 技術分析
  • 特許分析
  • 2025年～2026年の主な会議とイベント
  • ケーススタディ分析
  • 関税および規制分析
  • ポーターのファイブフォース分析
  • 主要な利害関係者と購入基準
  • パイプライン分析
  • AI/生成AIがヒトのマイクロバイオーム市場に与える影響
  • 米国関税がヒトマイクロバイオーム市場に与える影響
  • マイクロバイオーム介入別GLP-1の副作用管理
  • ヒトマイクロバイオーム市場の将来動向

第6章 ヒトマイクロバイオーム市場（製品別）

  • イントロダクション
  • 医薬品
  • サプリメント
  • 診断

第7章 ヒトマイクロバイオーム医薬品・サプリメント市場（タイプ別）

  • イントロダクション
  • 細菌コンソーシアム移植（BCT）/糞便微生物移植（FMT）
  • 生菌製品（LBP）
  • その他

第8章 ヒトマイクロバイオーム市場（疾患別）

  • イントロダクション
  • 感染症
  • 胃腸疾患
  • 内分泌および代謝疾患
  • その他

第9章 ヒトマイクロバイオーム医薬品・サプリメント市場（投与経路別）

  • イントロダクション
  • 経口投与
  • 直腸投与

第10章 ヒトマイクロバイオーム製造市場（サービス別）

  • イントロダクション
  • 株の開発と最適化
  • 発酵と下流処理
  • 配合と充填/仕上げ
  • その他

第11章 ヒトマイクロバイオーム市場（エンドユーザー別）

  • イントロダクション
  • 病院・クリニック
  • 長期療養施設
  • その他

第12章 ヒトマイクロバイオーム市場（地域別）

  • イントロダクション
  • 北米
    • 北米のマクロ経済見通し
    • 米国
    • カナダ
  • 欧州
    • 欧州のマクロ経済見通し
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • アジア太平洋のマクロ経済見通し
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • その他
  • ラテンアメリカ
    • ラテンアメリカのマクロ経済見通し
    • ブラジル
    • その他
  • 中東
    • 中東のマクロ経済見通し
    • GCC諸国
    • その他
  • アフリカ
    • 成長を促進するためのマイクロバイオームに関する研究と取り組みの増加
    • アフリカのマクロ経済見通し

第13章 競合情勢

  • イントロダクション
  • 主要参入企業の戦略/強み
  • 収益分析、2022年～2024年
  • 市場シェア分析、2024年
  • 企業評価と財務指標
  • ブランド/製品比較
  • 企業評価マトリックス：主要参入企業、2024年
  • 企業評価マトリックス：スタートアップ/中小企業、2024年
  • 競合シナリオ

第14章 企業プロファイル

  • 主要参入企業
    • INTERNATIONAL FLAVORS & FRAGRANCES INC.
    • SEED HEALTH, INC.
    • SERES THERAPEUTICS
    • FERRING B.V.
    • PENDULUM
    • OPTIBIOTIX HEALTH PLC
    • BIOGAIA
    • MAAT PHARMA
    • MICROBA
    • BIOMEBANK
    • BIOHM HEALTH
    • ACTIAL FARMACEUTICA SRL
    • RESBIOTIC
    • INFINANT HEALTH INC.
    • EXEGI PHARMA
    • FINCH THERAPEUTICS GROUP, INC.
    • INFANT BACTERIAL THERAPEUTICS AB
    • VIOME LIFESCIENCES
    • GENOVA DIAGNOSTICS
  • その他の企業
    • AOBIOME
    • GUANGZHOU ZHIYI BIOTECHNOLOGY CO., LTD.
    • NUBIYOTA
    • OXTHERA
    • NEXBIOME
    • VEDANTA BIOSCIENCES, INC.
    • ENTEROME
    • APSEN FARMACEUTICA
    • METAGEN, INC.
    • SNIPR BIOME
    • MIKROBIOMIK
    • SYNLOGIC
    • GENETIC ANALYSIS
    • METABIOMICS
    • SUN GENOMICS, INC.

第15章 付録

図表

List of Tables

  • TABLE 1 HUMAN MICROBIOME MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS
  • TABLE 3 HUMAN MICROBIOME MARKET: RISK ANALYSIS
  • TABLE 4 HUMAN MICROBIOME MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
  • TABLE 5 INDUSTRY COLLABORATIONS IN HUMAN MICROBIOME MARKET, 2022-2024
  • TABLE 6 LIST OF STARTUPS/SMES IN HUMAN MICROBIOME MARKET
  • TABLE 7 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022-2024 (USD)
  • TABLE 8 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2022-2024 (USD)
  • TABLE 9 HUMAN MICROBIOME MARKET: MAJOR INVESTMENT AND FUNDING, 2022-2024
  • TABLE 10 HUMAN MICROBIOME MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2023-2024
  • TABLE 11 HUMAN MICROBIOME MARKET: KEY CONFERENCES AND EVENTS, 2025-2026
  • TABLE 12 TARIFF DATA FOR HS CODE 3002.90
  • TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 REGULATORY LANDSCAPE OF LIVE BIOTHERAPEUTIC PRODUCTS
  • TABLE 18 HUMAN MICROBIOME MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%)
  • TABLE 20 KEY BUYING CRITERIA, BY END USER
  • TABLE 21 KEY PLAYERS IMPLEMENTING AI IN HUMAN MICROBIOME
  • TABLE 22 COMPANIES LEVERAGING AI IN HUMAN MICROBIOME MARKET
  • TABLE 23 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 24 KEY PRODUCT-RELATED TARIFF: PHARMACEUTICAL PRODUCTS, MISCELLANEOUS EDIBLE PREPARATIONS, AND PRODUCTS OF ANIMAL ORIGIN
  • TABLE 25 CRITICAL COMPONENTS EXPOSED TO TARIFF CHANGES
  • TABLE 26 HUMAN MICROBIOME SUPPLEMENTS POSITIONED AS GLP-1 SUPPORT
  • TABLE 27 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 28 HUMAN MICROBIOME DRUGS IN CLINICAL STAGE
  • TABLE 29 HUMAN MICROBIOME DRUGS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 30 NORTH AMERICA: HUMAN MICROBIOME DRUGS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 31 ASIA PACIFIC: HUMAN MICROBIOME DRUGS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 32 HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 33 HUMAN MICROBIOME SUPPLEMENTS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 34 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 35 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 36 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 37 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 38 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 39 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 40 HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 41 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 42 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 43 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 44 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 45 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 46 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PROBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 47 HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 48 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 49 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 50 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 51 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 52 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 53 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR PREBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 54 HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 55 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 56 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 57 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 58 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 59 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 60 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET FOR SYNBIOTICS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 61 HUMAN MICROBIOME DIAGNOSTICS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 62 NORTH AMERICA: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 63 EUROPE: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 64 ASIA PACIFIC: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 65 LATIN AMERICA: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 66 MIDDLE EAST: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 67 GCC COUNTRIES: HUMAN MICROBIOME DIAGNOSTICS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 68 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 69 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT), BY REGION, 2023-2031 (USD MILLION)
  • TABLE 70 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT), BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 71 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT), BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 72 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY REGION, 2023-2031 (USD MILLION)
  • TABLE 73 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 74 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 75 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 76 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 77 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY REGION, 2023-2031 (USD MILLION)
  • TABLE 78 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR LIVE BACTERIA PRODUCTS (LBP), BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 79 HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 80 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 81 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 82 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 83 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 84 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 85 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENT MARKET FOR OTHER MICROBIOME TYPES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 86 HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
  • TABLE 87 DEVELOPMENT OF MICROBIOME-BASED ANTI-BACTERIAL DRUGS FOR INFECTIOUS DISEASES
  • TABLE 88 HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 89 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 90 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 91 HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 92 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 93 EUROPE: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 94 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 95 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 96 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 97 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 98 HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 99 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 100 EUROPE: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 101 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 102 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 103 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 104 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 105 HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 106 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 107 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 108 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 109 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 110 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 111 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 112 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
  • TABLE 113 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 114 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 115 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 116 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 117 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 118 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 119 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 120 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR RECTAL ROUTE OF ADMINISTRATION, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 121 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR RECTAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 122 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET FOR RECTAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 123 HUMAN MICROBIOME MANUFACTURING MARKET, BY SERVICE, 2023-2031 (USD MILLION)
  • TABLE 124 HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 125 HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 126 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 127 EUROPE: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 128 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 129 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 130 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 131 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 132 HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 133 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 134 EUROPE: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 135 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 136 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 137 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 138 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 139 HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 140 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 141 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 142 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 143 LATIN AMERICA: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 144 MIDDLE EAST: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 145 GCC COUNTRIES: HUMAN MICROBIOME MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 146 HUMAN MICROBIOME MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 147 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 148 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 149 NORTH AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 150 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 151 NORTH AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
  • TABLE 152 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
  • TABLE 153 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 154 NORTH AMERICA: KEY MACROECONOMIC INDICATORS
  • TABLE 155 US: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 156 US: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 157 US: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 158 US: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
  • TABLE 159 US: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
  • TABLE 160 US: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 161 CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 162 CANADA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 163 CANADA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 164 CANADA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
  • TABLE 165 CANADA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
  • TABLE 166 CANADA: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 167 EUROPE: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 168 EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 169 EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 170 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 171 EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
  • TABLE 172 EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
  • TABLE 173 EUROPE: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 174 EUROPE: KEY MACROECONOMIC INDICATORS
  • TABLE 175 GERMANY: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 176 GERMANY: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 177 GERMANY: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 178 GERMANY: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
  • TABLE 179 GERMANY: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
  • TABLE 180 GERMANY: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 181 UK: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 182 UK: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 183 UK: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 184 UK: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
  • TABLE 185 UK: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
  • TABLE 186 UK: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 187 HUMAN MICROBIOME STARTUPS IN FRANCE
  • TABLE 188 FRANCE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 189 FRANCE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 190 FRANCE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 191 FRANCE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
  • TABLE 192 FRANCE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
  • TABLE 193 FRANCE: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 194 ITALY: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 195 ITALY: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 196 ITALY: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 197 ITALY: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
  • TABLE 198 ITALY: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
  • TABLE 199 ITALY: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 200 SPAIN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 201 SPAIN: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 202 SPAIN: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 203 SPAIN: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
  • TABLE 204 SPAIN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
  • TABLE 205 SPAIN: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 206 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 207 REST OF EUROPE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 208 REST OF EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 209 REST OF EUROPE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
  • TABLE 210 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
  • TABLE 211 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 212 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 213 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 214 ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 215 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 216 ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
  • TABLE 217 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
  • TABLE 218 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 219 ASIA PACIFIC: MACROECONOMIC INDICATORS
  • TABLE 220 CHINA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 221 CHINA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 222 CHINA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 223 CHINA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
  • TABLE 224 CHINA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
  • TABLE 225 CHINA: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 226 JAPAN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 227 JAPAN: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 228 JAPAN: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 229 JAPAN: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
  • TABLE 230 JAPAN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
  • TABLE 231 JAPAN: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 232 HUMAN MICROBIOME DIAGNOSTICS COMPANIES IN INDIA
  • TABLE 233 INDIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 234 INDIA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 235 INDIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 236 INDIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
  • TABLE 237 INDIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
  • TABLE 238 INDIA: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 239 SOUTH KOREA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 240 SOUTH KOREA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 241 SOUTH KOREA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 242 SOUTH KOREA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
  • TABLE 243 SOUTH KOREA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
  • TABLE 244 SOUTH KOREA: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 245 AUSTRALIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 246 AUSTRALIA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 247 AUSTRALIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 248 AUSTRALIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
  • TABLE 249 AUSTRALIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
  • TABLE 250 AUSTRALIA: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 251 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 252 REST OF ASIA PACIFIC: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 253 REST OF ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 254 REST OF ASIA PACIFIC: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
  • TABLE 255 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
  • TABLE 256 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 257 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 258 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 259 LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 260 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 261 LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
  • TABLE 262 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
  • TABLE 263 LATIN AMERICA: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 264 LATIN AMERICA: KEY MACROECONOMIC INDICATORS
  • TABLE 265 BRAZIL: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 266 BRAZIL: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 267 BRAZIL: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 268 BRAZIL: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
  • TABLE 269 BRAZIL: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
  • TABLE 270 BRAZIL: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 271 REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 272 REST OF LATIN AMERICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 273 REST OF LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 274 REST OF LATIN AMERICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
  • TABLE 275 REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
  • TABLE 276 REST OF LATIN AMERICA: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 277 MIDDLE EAST: HUMAN MICROBIOME MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 278 MIDDLE EAST: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 279 MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 280 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 281 MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
  • TABLE 282 MIDDLE EAST: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
  • TABLE 283 MIDDLE EAST: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 284 MIDDLE EAST: KEY MACROECONOMIC INDICATORS
  • TABLE 285 GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 286 GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 287 GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 288 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 289 GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
  • TABLE 290 GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
  • TABLE 291 GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 292 SAUDI ARABIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 293 SAUDI ARABIA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 294 SAUDI ARABIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 295 SAUDI ARABIA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
  • TABLE 296 SAUDI ARABIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
  • TABLE 297 SAUDI ARABIA: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 298 UAE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 299 UAE: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 300 UAE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 301 UAE: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
  • TABLE 302 UAE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
  • TABLE 303 UAE: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 304 REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 305 REST OF GCC COUNTRIES: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 306 REST OF GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 307 REST OF GCC COUNTRIES: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
  • TABLE 308 REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
  • TABLE 309 REST OF GCC COUNTRIES: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 310 REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 311 REST OF MIDDLE EAST: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 312 REST OF MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 313 REST OF MIDDLE EAST: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
  • TABLE 314 REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
  • TABLE 315 REST OF MIDDLE EAST: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 316 AFRICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 317 AFRICA: HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 318 AFRICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 319 AFRICA: HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2031 (USD MILLION)
  • TABLE 320 AFRICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2031 (USD MILLION)
  • TABLE 321 AFRICA: HUMAN MICROBIOME MARKET, BY END USER, 2023-2031 (USD MILLION)
  • TABLE 322 AFRICA: KEY MACROECONOMIC INDICATORS
  • TABLE 323 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HUMAN MICROBIOME MARKET, JANUARY 2022-JULY 2025
  • TABLE 324 HUMAN MICROBIOME MARKET: DEGREE OF COMPETITION, 2024
  • TABLE 325 HUMAN MICROBIOME MARKET: REGION FOOTPRINT
  • TABLE 326 HUMAN MICROBIOME MARKET: DRUG & SUPPLEMENT FOOTPRINT
  • TABLE 327 HUMAN MICROBIOME MARKET: TYPE FOOTPRINT
  • TABLE 328 HUMAN MICROBIOME MARKET: DISEASE FOOTPRINT
  • TABLE 329 HUMAN MICROBIOME MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 330 HUMAN MICROBIOME MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 331 HUMAN MICROBIOME MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JULY 2025
  • TABLE 332 HUMAN MICROBIOME MARKET: DEALS, JANUARY 2022-JULY 2025
  • TABLE 333 HUMAN MICROBIOME MARKET: EXPANSIONS, JANUARY 2022-JULY 2025
  • TABLE 334 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY OVERVIEW
  • TABLE 335 INTERNATIONAL FLAVORS & FRAGRANCES INC.: PRODUCTS OFFERED
  • TABLE 336 INTERNATIONAL FLAVORS & FRAGRANCES INC.: DEALS, JANUARY 2022-JULY 2025
  • TABLE 337 INTERNATIONAL FLAVORS & FRAGRANCES INC.: EXPANSIONS, JANUARY 2022-JULY 2025
  • TABLE 338 SEED HEALTH, INC.: COMPANY OVERVIEW
  • TABLE 339 SEED HEALTH, INC.: PRODUCTS OFFERED
  • TABLE 340 SEED HEALTH, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JULY 2025
  • TABLE 341 SEED HEALTH, INC.: DEALS, JANUARY 2022-JULY 2025
  • TABLE 342 SEED HEALTH, INC.: EXPANSIONS, JANUARY 2022-JULY 2025
  • TABLE 343 SERES THERAPEUTICS: COMPANY OVERVIEW
  • TABLE 344 SERES THERAPEUTICS: PRODUCTS OFFERED
  • TABLE 345 SERES THERAPEUTICS: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JULY 2025
  • TABLE 346 SERES THERAPEUTICS: DEALS, JANUARY 2022-JULY 2025
  • TABLE 347 FERRING B.V.: COMPANY OVERVIEW
  • TABLE 348 FERRING B.V.: PRODUCTS OFFERED
  • TABLE 349 FERRING B.V.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JULY 2025
  • TABLE 350 FERRING B.V.: DEALS, JANUARY 2022-JULY 2025
  • TABLE 351 PENDULUM: COMPANY OVERVIEW
  • TABLE 352 PENDULUM: PRODUCTS OFFERED
  • TABLE 353 PENDULUM: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JULY 2025
  • TABLE 354 PENDULUM: DEALS, JANUARY 2022-JULY 2025
  • TABLE 355 OPTIBIOTIX HEALTH PLC: COMPANY OVERVIEW
  • TABLE 356 OPTIBIOTIX HEALTH PLC: PRODUCTS OFFERED
  • TABLE 357 OPTIBIOTIX HEALTH PLC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JULY 2025
  • TABLE 358 OPTIBIOTIX HEALTH PLC: DEALS, JANUARY 2022-JULY 2025
  • TABLE 359 BIOGAIA: COMPANY OVERVIEW
  • TABLE 360 BIOGAIA: PRODUCTS OFFERED
  • TABLE 361 BIOGAIA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JULY 2025
  • TABLE 362 BIOGAIA: DEALS, JANUARY 2022-JULY 2025
  • TABLE 363 BIOGAIA: EXPANSIONS, JANUARY 2022-JULY 2025
  • TABLE 364 MAAT PHARMA: COMPANY OVERVIEW
  • TABLE 365 MAAT PHARMA: PRODUCTS OFFERED
  • TABLE 366 MAAT PHARMA: DEALS, JANUARY 2022-JULY 2025
  • TABLE 367 MAAT PHARMA: OTHER DEVELOPMENTS, JANUARY 2022-JULY 2025
  • TABLE 368 MICROBA: COMPANY OVERVIEW
  • TABLE 369 MICROBA: PRODUCTS OFFERED
  • TABLE 370 MICROBA: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JULY 2025
  • TABLE 371 BIOMEBANK: COMPANY OVERVIEW
  • TABLE 372 BIOMEBANK: PRODUCTS OFFERED
  • TABLE 373 BIOMEBANK: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JULY 2025
  • TABLE 374 BIOMEBANK: DEALS, JANUARY 2022-JULY 2025
  • TABLE 375 BIOMEBANK: EXPANSIONS, JANUARY 2022-JULY 2025
  • TABLE 376 BIOHM HEALTH: COMPANY OVERVIEW
  • TABLE 377 BIOHM HEALTH: PRODUCTS OFFERED
  • TABLE 378 BIOHM HEALTH: DEALS, JANUARY 2022-JULY 2025
  • TABLE 379 ACTIAL FARMACEUTICA SRL: COMPANY OVERVIEW
  • TABLE 380 ACTIAL FARMACEUTICA SRL: PRODUCTS OFFERED
  • TABLE 381 RESBIOTIC: COMPANY OVERVIEW
  • TABLE 382 RESBIOTIC: PRODUCTS OFFERED
  • TABLE 383 RESBIOTIC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JULY 2025
  • TABLE 384 RESBIOTIC: DEALS, JANUARY 2022-JULY 2025
  • TABLE 385 RESBIOTIC: EXPANSIONS, JANUARY 2022-JULY 2025
  • TABLE 386 INFINANT HEALTH INC.: COMPANY OVERVIEW
  • TABLE 387 INFINANT HEALTH INC.: PRODUCTS OFFERED
  • TABLE 388 INFINANT HEALTH INC.: DEALS, JANUARY 2022-JULY 2025
  • TABLE 389 EXEGI PHARMA: COMPANY OVERVIEW
  • TABLE 390 EXEGI PHARMA: PRODUCTS OFFERED
  • TABLE 391 EXEGI PHARMA: DEALS, JANUARY 2022-JULY 2025
  • TABLE 392 FINCH THERAPEUTICS GROUP, INC.: COMPANY OVERVIEW
  • TABLE 393 FINCH THERAPEUTICS GROUP, INC.: PRODUCTS OFFERED
  • TABLE 394 FINCH THERAPEUTICS GROUP, INC.: DEALS, JANUARY 2022-JULY 2025
  • TABLE 395 INFANT BACTERIAL THERAPEUTICS AB: COMPANY OVERVIEW
  • TABLE 396 INFANT BACTERIAL THERAPEUTICS AB: PRODUCTS OFFERED
  • TABLE 397 VIOME LIFESCIENCES: COMPANY OVERVIEW
  • TABLE 398 VIOME LIFESCIENCES: PRODUCTS OFFERED
  • TABLE 399 VIOME LIFESCIENCES: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-JULY 2025
  • TABLE 400 GENOVA DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 401 GENOVA DIAGNOSTICS: PRODUCTS OFFERED
  • TABLE 402 AOBIOME: COMPANY OVERVIEW
  • TABLE 403 GUANGZHOU ZHIYI BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW
  • TABLE 404 NUBIYOTA: COMPANY OVERVIEW
  • TABLE 405 OXTHERA: COMPANY OVERVIEW
  • TABLE 406 NEXBIOME: COMPANY OVERVIEW
  • TABLE 407 VEDANTA BIOSCIENCES, INC.: COMPANY OVERVIEW
  • TABLE 408 ENTEROME: COMPANY OVERVIEW
  • TABLE 409 APSEN FARMACEUTICA: COMPANY OVERVIEW
  • TABLE 410 METAGEN, INC.: COMPANY OVERVIEW
  • TABLE 411 SNIPR BIOME: COMPANY OVERVIEW
  • TABLE 412 MIKROBIOMIK: COMPANY OVERVIEW
  • TABLE 413 SYNLOGIC: COMPANY OVERVIEW
  • TABLE 414 GENETIC ANALYSIS: COMPANY OVERVIEW
  • TABLE 415 METABIOMICS: COMPANY OVERVIEW
  • TABLE 416 SUN GENOMICS, INC.: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 HUMAN MICROBIOME MARKET SEGMENTATION AND REGIONAL SCOPE
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 HUMAN MICROBIOME MARKET: BREAKDOWN OF PRIMARIES
  • FIGURE 4 HUMAN MICROBIOME MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
  • FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2024
  • FIGURE 6 ILLUSTRATIVE EXAMPLE OF INTERNATIONAL FLAVORS & FRAGRANCES INC.: REVENUE SHARE ANALYSIS, 2024
  • FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 9 HUMAN MICROBIOME MARKET: CAGR PROJECTIONS
  • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • FIGURE 11 HUMAN MICROBIOME MARKET, BY PRODUCT, 2025 VS. 2031 (USD MILLION)
  • FIGURE 12 HUMAN MICROBIOME SUPPLEMENTS MARKET, BY TYPE, 2025 VS. 2031 (USD MILLION)
  • FIGURE 13 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE, 2024 VS. 2030 (USD MILLION)
  • FIGURE 14 HUMAN MICROBIOME MARKET, BY DISEASE, 2025 VS. 2031 (USD MILLION)
  • FIGURE 15 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION, 2025 VS. 2031 (USD MILLION)
  • FIGURE 16 HUMAN MICROBIOME MARKET, BY END USER, 2024 VS. 2030 (USD MILLION)
  • FIGURE 17 HUMAN MICROBIOME MARKET: GEOGRAPHICAL SNAPSHOT
  • FIGURE 18 RISING DEMAND FOR PERSONALIZED MEDICINE AND ADVANCEMENTS IN MICROBIOME SEQUENCING TO DRIVE MARKET
  • FIGURE 19 US AND LIVE BACTERIA PRODUCTS (LBP) SEGMENT LED NORTH AMERICAN MARKET IN 2024
  • FIGURE 20 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT) SEGMENT TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 21 US TO DOMINATE GLOBAL MARKET DURING FORECAST PERIOD
  • FIGURE 22 HOSPITALS & CLINICS SEGMENT TO HOLD LARGEST MARKET SHARE IN 2025
  • FIGURE 23 HUMAN MICROBIOME MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 24 COMMERCIALIZATION ASPECTS OF MICROBIOMES FOR DRUGS VS. SUPPLEMENTS
  • FIGURE 25 HUMAN MICROBIOME MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 26 DISRUPTION INDEX: MARKET READINESS VS. ADOPTION VS. MATURITY
  • FIGURE 28 AVERAGE SELLING PRICE OF HUMAN MICROBIOME DRUGS, BY KEY PLAYER, 2024 (USD)
  • FIGURE 29 AVERAGE SELLING PRICE OF HUMAN MICROBIOME DIAGNOSTICS, BY KEY PLAYER, 2024 (USD)
  • FIGURE 30 AVERAGE SELLING PRICE TREND OF HUMAN MICROBIOME SUPPLEMENTS & DIAGNOSTICS, BY TYPE, 2022-2024 (USD)
  • FIGURE 31 AVERAGE SELLING PRICE OF HUMAN MICROBIOME SUPPLEMENTS, BY REGION, 2024 (USD)
  • FIGURE 32 VALUE CHAIN ANALYSIS FOR HUMAN MICROBIOME DRUGS
  • FIGURE 33 VALUE CHAIN ANALYSIS FOR HUMAN MICROBIOME SUPPLEMENTS
  • FIGURE 34 VALUE CHAIN ANALYSIS FOR HUMAN MICROBIOME DIAGNOSTICS
  • FIGURE 35 HUMAN MICROBIOME MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 36 HUMAN MICROBIOME MARKET: INVESTMENT AND FUNDING SCENARIO, 2022-2024
  • FIGURE 37 HUMAN MICROBIOME MARKET: PATENT ANALYSIS, JANUARY 2014-DECEMBER 2024
  • FIGURE 38 REGULATORY LANDSCAPE OF LIVE BACTERIA PRODUCTS (LBP)
  • FIGURE 39 HUMAN MICROBIOME MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 40 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
  • FIGURE 41 KEY BUYING CRITERIA, BY END USER
  • FIGURE 42 HUMAN MICROBIOME PIPELINE, BY DISEASE
  • FIGURE 43 HUMAN MICROBIOME PIPELINE, BY PHASE
  • FIGURE 44 HUMAN MICROBIOME PIPELINE, BY REGION
  • FIGURE 45 IMPACT OF AI/GEN AI ON HUMAN MICROBIOME MARKET
  • FIGURE 46 AI USE CASES
  • FIGURE 47 NORTH AMERICA: HUMAN MICROBIOME MARKET SNAPSHOT
  • FIGURE 48 ASIA PACIFIC: HUMAN MICROBIOME MARKET SNAPSHOT
  • FIGURE 49 REVENUE ANALYSIS OF KEY PLAYERS IN HUMAN MICROBIOME MARKET, 2022-2024 (USD MILLION)
  • FIGURE 50 MARKET SHARE ANALYSIS OF KEY PLAYERS IN HUMAN MICROBIOME MARKET, 2024
  • FIGURE 51 EV/EBITDA OF KEY PLAYERS
  • FIGURE 52 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY PLAYERS
  • FIGURE 53 HUMAN MICROBIOME MARKET: BRAND/PRODUCT COMPARISON
  • FIGURE 54 HUMAN MICROBIOME MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 55 HUMAN MICROBIOME MARKET: COMPANY FOOTPRINT
  • FIGURE 56 HUMAN MICROBIOME MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 57 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 58 SERES THERAPEUTICS: COMPANY SNAPSHOT (2023)
  • FIGURE 59 FERRING B.V.: COMPANY SNAPSHOT (2024)
  • FIGURE 60 OPTIBIOTIX HEALTH PLC: COMPANY SNAPSHOT (2024)
  • FIGURE 61 BIOGAIA: COMPANY SNAPSHOT (2024)
  • FIGURE 62 MAAT PHARMA: COMPANY SNAPSHOT (2024)
  • FIGURE 63 MICROBA: COMPANY SNAPSHOT (2024)
  • FIGURE 64 FINCH THERAPEUTICS GROUP, INC.: COMPANY SNAPSHOT (2023)
目次
Product Code: BT 2711

The Human Microbiome market is expected to reach USD 7.09 billion in 2031 from USD 1.40 billion in 2024, at a CAGR of 31.0% during the forecast period.

Scope of the Report
Years Considered for the Study2024-2031
Base Year2024
Forecast Period2025-2031
Units ConsideredValue (USD billion)
SegmentsProduct, Disease, Drugs & Supplements Type, Drugs & Supplements Route of Administration, End User, Manufacturing Services, and Region
Regions coveredNorth America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa

Factors such as the collaborative efforts between the microbiome industry and academia for microbiome research and the growing demand for personalized medicine are driving the growth of the human microbiome market. However, complex regulatory policies adversely impact the commercialization of microbiomes, restraining market growth.

The probiotics segment accounted for the largest share of the human microbiome supplements segment in 2024.

Human Microbiome Market - IMG1

The market is segmented into human microbiome drugs, human microbiome supplements, and human microbiome diagnostics. The human microbiome supplements are analyzed across three key products: probiotics, prebiotics, and synbiotics. The segment with the biggest share in the human microbiome market in 2024 is probiotics. This dominance is attributed to their widespread use, strong consumer awareness, and established presence in over-the-counter health and wellness products. Probiotics are commonly used to support digestive health, boost immunity, and maintain gut microbial balance, making them a routine part of preventive healthcare. They are available in various formats, including capsules, powders, beverages, and functional foods, enhancing accessibility and consumer adoption. Additionally, a large body of clinical research supports the efficacy of specific probiotic strains, reinforcing trust among consumers and healthcare providers. The ability to pair probiotics with other bioactives like prebiotics or vitamins has further expanded their appeal across various demographics. Collectively, these factors have made probiotics the leading product type in the human microbiome supplements segment.

In 2024, the gastrointestinal diseases segment accounted for the largest share of the market.

The human microbiome market is segmented into gastrointestinal diseases, infectious diseases, endocrine & metabolic disorders, and other diseases. In 2024, the gastrointestinal diseases segment accounted for the largest share of the market. This is driven by the strong association between gut microbiota and conditions such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), ulcerative colitis, and Crohn's disease. These chronic disorders have a high global prevalence and often require long-term management, creating demand for alternative and adjunctive therapies that target the gut microbiome.

A growing body of research supports the role of microbial imbalances in the development and progression of gastrointestinal conditions, prompting increased investment in microbiome-based diagnostics and treatments. Several clinical-stage products targeting IBD and IBS are in development, reflecting scientific interest and unmet patient needs. The availability of microbiome supplements aimed at digestive health, such as probiotics and synbiotics, has further expanded consumer access and contributed to market growth in this segment.

In 2024, North America accounted for the largest share of the human microbiome market.

North America accounted for the largest share of the human microbiome market in 2024. This is due to several factors, including a strong presence of key market players, advanced healthcare infrastructure, and high levels of investment in microbiome research and development. The region hosts numerous clinical trials and academic collaborations focused on microbiome science, particularly in the United States. Regulatory support has also contributed to market growth, with the US FDA approving the first microbiome-based therapeutics, such as VOWST and Rebyota, setting important regulatory precedents. In addition, North America has a large and growing consumer base for microbiome supplements, particularly probiotics and synbiotics, driven by rising awareness of gut health and preventive wellness. High healthcare spending, increasing prevalence of chronic diseases, and favorable reimbursement policies further reinforce the leading position of North America in the global human microbiome market.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
  • By Designation: C-level Executives - 55%, Directors- 20%, and Others- 25%
  • By Region: North America -45%, Europe - 20%, Asia Pacific -20%, Latin America -10%, the Middle East- 3%, and Africa-2%

Seres Therapeutics (US), Ferring B.V. (Switzerland), BiomeBank (Australia), Seed Health, Inc. (US), International Flavors & Fragrances Inc. (US), Pendulum (US), Biohm Technologies (US), Actial Farmaceutica Srl (Italy), OptiBiotix Health Plc (UK), resbiotic (US), Infinant Health Inc (US), BioGaia (Sweden), ExeGi Pharma (US), Finch Therapeutics Group, Inc. (US), Infant Bacterial Therapeutics AB (Sweden), MaaT Pharma (France), Microba (Australia), Viome Life Sciences, Inc. (US), and Genova Diagnostics (US) are some of the key companies offering human microbiome drugs & supplements.

Research Coverage

This research report categorizes the Human Microbiome market by Product (Human Microbiome Drugs, Human Microbiome Supplements [Probiotics, Prebiotics, Synbiotics], Human Microbiome Diagnostics), Disease (Infectious disease, Gastrointestinal Disease, Endocrine, and metabolic disorders, Cancer, and Other Diseases), Drugs & Supplements Type (Bacterial Consortia Transplantation (BCT)/ Fecal Microbiota Transplantation (FMT), Peptides, Live Bacteria Products, and Others), Drugs & Supplements Route of Administration (Oral, Rectal), End User (Hospitals & Clinics, Long-term care Facilities, Other End Users), Manufacturing Service (Strain Development & Optimization, Fermentation & Downstream Processing, Formulation & Fill/Finish, Other Services) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the Human Microbiome market. A detailed analysis of the key industry players has been done to provide insights into their business overview, service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, and acquisitions, and recent developments associated with the Human Microbiome market. Competitive analysis of top players and upcoming startups in the human microbiome market ecosystem is covered in this report.

The scope of the report covers detailed information regarding the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the human microbiome market. A thorough analysis of the key industry players has been conducted to provide insights into their business overview, solutions, and services; key strategies; new product & service launches, acquisitions, and recent developments associated with the human microbiome market. This report covers the competitive analysis of upcoming startups in the human microbiome market ecosystem.

Key Benefits of Buying the Report

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Human Microbiome market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Collaborative initiatives between organizations, academia, and the microbiome industry, Increase in the number of Startups,/SMEs exploring the microbiome niche, Advancements in microbiome sequencing), restraints (Adverse impact of complex regulatory policies on commercialization of microbiomes, High investment in commercialization of microbiome drugs), opportunities (Increase in demand for personalized medicine, and Emergence of synbiotics), and challenges (Slow patient adoption of microbiome-based therapies and Complexities involved in development of microbiome therapies) influencing the growth of the market.

  • Product Development/Innovation: Detailed insights on newly launched products of the human microbiome market
  • Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
  • Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the Human Microbiome market

Competitive Assessment: Seres Therapeutics (US), Ferring B.V. (Switzerland), BiomeBank (Australia), Seed Health, Inc. (US), International Flavors & Fragrances Inc. (US), Pendulum (US), Biohm Technologies (US), Actial Farmaceutica Srl (Italy), OptiBiotix Health Plc (UK), resbiotic (US), Infinant Health Inc (US), BioGaia (Sweden), ExeGi Pharma (US), Finch Therapeutics Group, Inc. (US), Infant Bacterial Therapeutics AB (Sweden), MaaT Pharma (France), Microba (Australia), Viome Life Sciences, Inc. (US), and Genova Diagnostics (US) among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
    • 1.3.2 INCLUSIONS AND EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
  • 2.2 MARKET SIZE ESTIMATION METHODOLOGY
    • 2.2.1 INSIGHTS FROM PRIMARY EXPERTS
    • 2.2.2 SEGMENTAL MARKET SIZE ESTIMATION
  • 2.3 GROWTH RATE PROJECTIONS
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
  • 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 HUMAN MICROBIOME MARKET OVERVIEW
  • 4.2 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY TYPE AND COUNTRY, 2024
  • 4.3 HUMAN MICROBIOME MARKET, BY TYPE, 2025 VS. 2031
  • 4.4 HUMAN MICROBIOME MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.5 HUMAN MICROBIOME MARKET, BY END USER, 2025

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Collaborative initiatives between organizations and academia
      • 5.2.1.2 Increasing number of startups/SMEs exploring microbiome
      • 5.2.1.3 Advancements in microbiome sequencing
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Complex regulatory policies
      • 5.2.2.2 High investments in commercializing microbiome drugs
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increasing demand for personalized medicines
      • 5.2.3.2 Emergence of postbiotics
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Slow patient adoption of microbiome-based therapies
      • 5.2.4.2 Complexities in developing microbiome therapies
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
    • 5.3.1 DISRUPTION INDEX: MARKET READINESS VS. ADOPTION VS. MATURITY
      • 5.3.1.1 Market readiness
      • 5.3.1.2 Adoption
      • 5.3.1.3 Maturity
  • 5.4 PRICING ANALYSIS
    • 5.4.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022-2024
    • 5.4.2 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2022-2024
  • 5.5 VALUE CHAIN ANALYSIS
    • 5.5.1 HUMAN MICROBIOME DRUGS
    • 5.5.2 HUMAN MICROBIOME SUPPLEMENTS
    • 5.5.3 HUMAN MICROBIOME DIAGNOSTICS
  • 5.6 ECOSYSTEM ANALYSIS
    • 5.6.1 ECOSYSTEM SHIFT
      • 5.6.1.1 Specialized raw material and data suppliers
      • 5.6.1.2 Hot-bet innovator startups
      • 5.6.1.3 Integrated end users and prosumer models
      • 5.6.1.4 Regulatory and quality assurance orchestrators
      • 5.6.1.5 Diagnostics-driven personalization
      • 5.6.1.6 Microbiome-as-a-Service (Maas)
    • 5.6.2 EMERGING BUSINESS MODELS
      • 5.6.2.1 Emerging B2C model
      • 5.6.2.2 Personalized supplements model
    • 5.6.3 INTERCONNECTED MARKET DYNAMICS
  • 5.7 INVESTMENT AND FUNDING SCENARIO
    • 5.7.1 MAJOR INVESTMENTS AND FUNDING BY KEY MARKET PLAYERS
    • 5.7.2 OTHER INVESTMENTS AND FUNDING
  • 5.8 TECHNOLOGY ANALYSIS
    • 5.8.1 KEY TECHNOLOGIES
      • 5.8.1.1 Whole-genome sequencing
      • 5.8.1.2 16s RNA sequencing method
      • 5.8.1.3 Nanopore sequencing
    • 5.8.2 COMPLEMENTARY TECHNOLOGIES
      • 5.8.2.1 Metatranscriptomics
      • 5.8.2.2 Metagenomics
      • 5.8.2.3 Metabolomics
    • 5.8.3 ADJACENT TECHNOLOGIES
      • 5.8.3.1 Sample preparation
      • 5.8.3.2 Data analysis
      • 5.8.3.3 Library synthesis
  • 5.9 PATENT ANALYSIS
  • 5.10 KEY CONFERENCES AND EVENTS, 2025-2026
  • 5.11 CASE STUDY ANALYSIS
    • 5.11.1 EFFECT OF REBYOTA ON QUALITY OF LIFE IN PATIENTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION
    • 5.11.2 ECOSPOR IV STUDY OF VOWST FOR CLOSTRIDIOIDES DIFFICILE INFECTION
    • 5.11.3 DELONG#3 STUDY FOR QUALITY OF LIFE IMPROVEMENT BY VSL#3 PROBIOTIC IN POST-COVID-19 PATIENTS
  • 5.12 TARIFF AND REGULATORY ANALYSIS
    • 5.12.1 TARIFF DATA (HS CODE 3002.90)
    • 5.12.2 REGULATORY LANDSCAPE
      • 5.12.2.1 North America
        • 5.12.2.1.1 US
        • 5.12.2.1.2 Canada
      • 5.12.2.2 Europe
        • 5.12.2.2.1 UK
      • 5.12.2.3 Asia Pacific
        • 5.12.2.3.1 China
        • 5.12.2.3.2 Japan
        • 5.12.2.3.3 South Korea
        • 5.12.2.3.4 Australia
        • 5.12.2.3.5 Rest of Asia Pacific
    • 5.12.3 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.13 PORTER'S FIVE FORCES ANALYSIS
    • 5.13.1 BARGAINING POWER OF SUPPLIERS
    • 5.13.2 BARGAINING POWER OF BUYERS
    • 5.13.3 THREAT OF NEW ENTRANTS
    • 5.13.4 THREAT OF SUBSTITUTES
    • 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.14.2 BUYING CRITERIA
  • 5.15 PIPELINE ANALYSIS
  • 5.16 IMPACT OF AI/GEN AI ON HUMAN MICROBIOME MARKET
    • 5.16.1 INTRODUCTION
    • 5.16.2 MARKET POTENTIAL OF AI IN HUMAN MICROBIOME MARKET
    • 5.16.3 AI USE CASES
    • 5.16.4 KEY PLAYERS IMPLEMENTING AI
    • 5.16.5 FUTURE OF GENERATIVE AI IN HUMAN MICROBIOME MARKET
  • 5.17 IMPACT OF US TARIFF ON HUMAN MICROBIOME MARKET
    • 5.17.1 KEY TARIFF RATES
    • 5.17.2 PRICE IMPACT ANALYSIS
    • 5.17.3 KEY IMPACT ON COUNTRY/REGION
      • 5.17.3.1 US
      • 5.17.3.2 Europe
      • 5.17.3.3 Asia Pacific
      • 5.17.3.4 Rest of the World
    • 5.17.4 IMPACT ON END-USE INDUSTRY
      • 5.17.4.1 Hospitals and clinics
      • 5.17.4.2 Long-term care facilities
  • 5.18 MANAGING GLP-1 SIDE EFFECTS WITH MICROBIOME INTERVENTIONS
  • 5.19 FUTURE TRENDS IN HUMAN MICROBIOME MARKET
    • 5.19.1 TYPE
    • 5.19.2 DISEASE
    • 5.19.3 END USER

6 HUMAN MICROBIOME MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
  • 6.2 DRUGS
    • 6.2.1 GROWING PIPELINE OF MICROBIOME-BASED DRUGS IN LATE-STAGE CLINICAL TRIALS TO DRIVE MARKET
  • 6.3 SUPPLEMENTS
    • 6.3.1 PROBIOTICS
      • 6.3.1.1 Increasing consumer awareness about probiotics for improved gut health and immunity to aid growth
    • 6.3.2 PREBIOTICS
      • 6.3.2.1 Rising development of targeted prebiotics to expedite growth
    • 6.3.3 SYNBIOTICS
      • 6.3.3.1 Growing demand for personalized treatment and rising incidence of dysbiosis to fuel market
  • 6.4 DIAGNOSTICS
    • 6.4.1 INCREASING PRODUCT LAUNCHES AND TECHNOLOGY TRANSFER TO FACILITATE GROWTH

7 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY TYPE

  • 7.1 INTRODUCTION
  • 7.2 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT)
    • 7.2.1 ADVANCEMENTS IN CLINICAL TRIALS FOR TREATMENT OF C. DIFFICILE INFECTION TO AUGMENT GROWTH
  • 7.3 LIVE BACTERIA PRODUCTS (LBP)
    • 7.3.1 INCREASING CONSUMER FOCUS ON PREVENTIVE HEALTH TO AID GROWTH
  • 7.4 OTHER MICROBIOME TYPES

8 HUMAN MICROBIOME MARKET, BY DISEASE

  • 8.1 INTRODUCTION
  • 8.2 INFECTIOUS DISEASES
    • 8.2.1 EMERGENCE OF MULTIDRUG-RESISTANT BACTERIA TO FOSTER GROWTH
  • 8.3 GASTROINTESTINAL DISEASES
    • 8.3.1 INCREASING DEMAND FOR PERSONALIZED THERAPIES TO AID GROWTH
  • 8.4 ENDOCRINE & METABOLIC DISORDERS
    • 8.4.1 DEVELOPMENT OF MICROBIOME MODULATORS FOR METABOLIC DISORDERS TO BOOST MARKET
  • 8.5 OTHER DISEASES

9 HUMAN MICROBIOME DRUGS & SUPPLEMENTS MARKET, BY ROUTE OF ADMINISTRATION

  • 9.1 INTRODUCTION
  • 9.2 ORAL ROUTE OF ADMINISTRATION
    • 9.2.1 WIDESPREAD PATIENT ACCEPTANCE AND EXTENSIVE PRODUCT OFFERINGS TO ENCOURAGE GROWTH
  • 9.3 RECTAL ROUTE OF ADMINISTRATION
    • 9.3.1 ABILITY TO RESTORE HEALTHY GUT TO FACILITATE GROWTH

10 HUMAN MICROBIOME MANUFACTURING MARKET, BY SERVICE

  • 10.1 INTRODUCTION
  • 10.2 STRAIN DEVELOPMENT & OPTIMIZATION
    • 10.2.1 RISING DEMAND FOR TARGETED, STRAIN-SPECIFIC MICROBIOME THERAPIES TO BOOST MARKET
  • 10.3 FERMENTATION & DOWNSTREAM PROCESSING
    • 10.3.1 GROWING DEMAND FOR CLINICAL-STAGE BIOTHERAPEUTICS TO DRIVE MARKET
  • 10.4 FORMULATION & FILL/FINISH
    • 10.4.1 INCREASING STUDIES ON LIVE BIOTHERAPEUTIC PRODUCTS TO PROMOTE GROWTH
  • 10.5 OTHER SERVICES

11 HUMAN MICROBIOME MARKET, BY END USER

  • 11.1 INTRODUCTION
  • 11.2 HOSPITALS & CLINICS
    • 11.2.1 AVAILABILITY OF ADVANCED HEALTHCARE INFRASTRUCTURE AND EXPERTISE TO AUGMENT GROWTH
  • 11.3 LONG-TERM CARE FACILITIES
    • 11.3.1 NEED FOR SPECIALIZED CARE AND CONTINUOUS MONITORING FOR PATIENTS WITH CHRONIC HEALTH CONDITIONS TO DRIVE MARKET
  • 11.4 OTHER END USERS

12 HUMAN MICROBIOME MARKET, BY REGION

  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    • 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 12.2.2 US
      • 12.2.2.1 Favorable government initiatives and booming diagnostics sector to drive market
    • 12.2.3 CANADA
      • 12.2.3.1 Increasing prevalence of chronic diseases to expedite growth
  • 12.3 EUROPE
    • 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 12.3.2 GERMANY
      • 12.3.2.1 Rapid increase in government and private funding to propel market
    • 12.3.3 UK
      • 12.3.3.1 Significant government investments in microbiome research and presence of microbiome companies to propel growth
    • 12.3.4 FRANCE
      • 12.3.4.1 Growing focus on developing new products and services using microbiome data to boost market
    • 12.3.5 ITALY
      • 12.3.5.1 Rise in research activities to encourage growth
    • 12.3.6 SPAIN
      • 12.3.6.1 Favorable microbiome research landscape to support growth
    • 12.3.7 REST OF EUROPE
  • 12.4 ASIA PACIFIC
    • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 12.4.2 CHINA
      • 12.4.2.1 Rapidly expanding healthcare industry to accelerate growth
    • 12.4.3 JAPAN
      • 12.4.3.1 Booming geriatric population to contribute to growth
    • 12.4.4 INDIA
      • 12.4.4.1 Increasing number of human microbiome diagnostic companies to augment growth
    • 12.4.5 SOUTH KOREA
      • 12.4.5.1 Booming bio-health market to advance growth
    • 12.4.6 AUSTRALIA
      • 12.4.6.1 Growing number of product approvals to boost markt
    • 12.4.7 REST OF ASIA PACIFIC
  • 12.5 LATIN AMERICA
    • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 12.5.2 BRAZIL
      • 12.5.2.1 Rising probiotics demand to drive market
    • 12.5.3 REST OF LATIN AMERICA
  • 12.6 MIDDLE EAST
    • 12.6.1 MACROECONOMIC OUTLOOK IN MIDDLE EAST
    • 12.6.2 GCC COUNTRIES
      • 12.6.2.1 Saudi Arabia
        • 12.6.2.1.1 Growing focus on healthcare infrastructure to fuel market
      • 12.6.2.2 UAE
        • 12.6.2.2.1 Increasing focus on immunotherapy and biotechnology to augment growth
      • 12.6.2.3 Rest of GCC countries
    • 12.6.3 REST OF MIDDLE EAST
  • 12.7 AFRICA
    • 12.7.1 INCREASING STUDIES AND INITIATIVES ON MICROBIOME TO PROMOTE GROWTH
    • 12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

13 COMPETITIVE LANDSCAPE

  • 13.1 INTRODUCTION
  • 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HUMAN MICROBIOME MARKET
  • 13.3 REVENUE ANALYSIS, 2022-2024
  • 13.4 MARKET SHARE ANALYSIS, 2024
  • 13.5 COMPANY VALUATION AND FINANCIAL METRICS
  • 13.6 BRAND/PRODUCT COMPARISON
  • 13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 13.7.1 STARS
    • 13.7.2 EMERGING LEADERS
    • 13.7.3 PERVASIVE PLAYERS
    • 13.7.4 PARTICIPANTS
    • 13.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 13.7.5.1 Company footprint
      • 13.7.5.2 Region footprint
      • 13.7.5.3 Product footprint
      • 13.7.5.4 Type footprint
      • 13.7.5.5 Disease footprint
  • 13.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 13.8.1 PROGRESSIVE COMPANIES
    • 13.8.2 RESPONSIVE COMPANIES
    • 13.8.3 DYNAMIC COMPANIES
    • 13.8.4 STARTING BLOCKS
    • 13.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
      • 13.8.5.1 Detailed list of key startups/SMEs
      • 13.8.5.2 Competitive benchmarking of key emerging players/startups
  • 13.9 COMPETITIVE SCENARIO
    • 13.9.1 PRODUCT LAUNCHES AND APPROVALS
    • 13.9.2 DEALS
    • 13.9.3 EXPANSIONS

14 COMPANY PROFILES

  • 14.1 KEY PLAYERS
    • 14.1.1 INTERNATIONAL FLAVORS & FRAGRANCES INC.
      • 14.1.1.1 Business overview
      • 14.1.1.2 Products offered
      • 14.1.1.3 Recent developments
        • 14.1.1.3.1 Deals
        • 14.1.1.3.2 Expansions
      • 14.1.1.4 MnM view
        • 14.1.1.4.1 Key strengths
        • 14.1.1.4.2 Strategic choices
        • 14.1.1.4.3 Weaknesses and competitive threats
    • 14.1.2 SEED HEALTH, INC.
      • 14.1.2.1 Business overview
      • 14.1.2.2 Products offered
      • 14.1.2.3 Recent developments
        • 14.1.2.3.1 Product launches and approvals
        • 14.1.2.3.2 Deals
        • 14.1.2.3.3 Expansions
      • 14.1.2.4 MnM view
        • 14.1.2.4.1 Key strengths
        • 14.1.2.4.2 Strategic choices
        • 14.1.2.4.3 Weaknesses and competitive threats
    • 14.1.3 SERES THERAPEUTICS
      • 14.1.3.1 Business overview
      • 14.1.3.2 Products offered
      • 14.1.3.3 Recent developments
        • 14.1.3.3.1 Product launches and approvals
        • 14.1.3.3.2 Deals
      • 14.1.3.4 MnM view
        • 14.1.3.4.1 Key strengths
        • 14.1.3.4.2 Strategic choices
        • 14.1.3.4.3 Weaknesses and competitive threats
    • 14.1.4 FERRING B.V.
      • 14.1.4.1 Business overview
      • 14.1.4.2 Products offered
      • 14.1.4.3 Recent developments
        • 14.1.4.3.1 Product launches and approvals
        • 14.1.4.3.2 Deals
      • 14.1.4.4 MnM view
        • 14.1.4.4.1 Key strengths
        • 14.1.4.4.2 Strategic choices
        • 14.1.4.4.3 Weaknesses and competitive threats
    • 14.1.5 PENDULUM
      • 14.1.5.1 Business overview
      • 14.1.5.2 Products offered
      • 14.1.5.3 Recent developments
        • 14.1.5.3.1 Product launches and approvals
        • 14.1.5.3.2 Deals
      • 14.1.5.4 MnM view
        • 14.1.5.4.1 Key strengths
        • 14.1.5.4.2 Strategic choices
        • 14.1.5.4.3 Weaknesses and competitive threats
    • 14.1.6 OPTIBIOTIX HEALTH PLC
      • 14.1.6.1 Business overview
      • 14.1.6.2 Products offered
      • 14.1.6.3 Recent developments
        • 14.1.6.3.1 Product launches and approvals
        • 14.1.6.3.2 Deals
    • 14.1.7 BIOGAIA
      • 14.1.7.1 Business overview
      • 14.1.7.2 Products offered
      • 14.1.7.3 Recent developments
        • 14.1.7.3.1 Product launches and approvals
        • 14.1.7.3.2 Deals
        • 14.1.7.3.3 Expansions
    • 14.1.8 MAAT PHARMA
      • 14.1.8.1 Business overview
      • 14.1.8.2 Products offered
      • 14.1.8.3 Recent developments
        • 14.1.8.3.1 Deals
        • 14.1.8.3.2 Other developments
    • 14.1.9 MICROBA
      • 14.1.9.1 Business overview
      • 14.1.9.2 Products offered
      • 14.1.9.3 Recent developments
        • 14.1.9.3.1 Product launches and approvals
    • 14.1.10 BIOMEBANK
      • 14.1.10.1 Business overview
      • 14.1.10.2 Products offered
      • 14.1.10.3 Recent developments
        • 14.1.10.3.1 Product launches and approvals
        • 14.1.10.3.2 Deals
        • 14.1.10.3.3 Expansions
    • 14.1.11 BIOHM HEALTH
      • 14.1.11.1 Business overview
      • 14.1.11.2 Products offered
      • 14.1.11.3 Recent developments
        • 14.1.11.3.1 Deals
    • 14.1.12 ACTIAL FARMACEUTICA SRL
      • 14.1.12.1 Business overview
      • 14.1.12.2 Products offered
    • 14.1.13 RESBIOTIC
      • 14.1.13.1 Business overview
      • 14.1.13.2 Products offered
      • 14.1.13.3 Recent developments
        • 14.1.13.3.1 Product launches and approvals
        • 14.1.13.3.2 Deals
        • 14.1.13.3.3 Expansions
    • 14.1.14 INFINANT HEALTH INC.
      • 14.1.14.1 Business overview
      • 14.1.14.2 Products offered
      • 14.1.14.3 Recent developments
        • 14.1.14.3.1 Deals
    • 14.1.15 EXEGI PHARMA
      • 14.1.15.1 Business overview
      • 14.1.15.2 Products offered
      • 14.1.15.3 Recent developments
        • 14.1.15.3.1 Deals
    • 14.1.16 FINCH THERAPEUTICS GROUP, INC.
      • 14.1.16.1 Business overview
      • 14.1.16.2 Products offered
      • 14.1.16.3 Recent developments
        • 14.1.16.3.1 Deals
    • 14.1.17 INFANT BACTERIAL THERAPEUTICS AB
      • 14.1.17.1 Business overview
      • 14.1.17.2 Products offered
    • 14.1.18 VIOME LIFESCIENCES
      • 14.1.18.1 Business overview
      • 14.1.18.2 Products offered
      • 14.1.18.3 Recent developments
        • 14.1.18.3.1 Product launches and approvals
    • 14.1.19 GENOVA DIAGNOSTICS
      • 14.1.19.1 Business overview
      • 14.1.19.2 Products offered
  • 14.2 OTHER PLAYERS
    • 14.2.1 AOBIOME
    • 14.2.2 GUANGZHOU ZHIYI BIOTECHNOLOGY CO., LTD.
    • 14.2.3 NUBIYOTA
    • 14.2.4 OXTHERA
    • 14.2.5 NEXBIOME
    • 14.2.6 VEDANTA BIOSCIENCES, INC.
    • 14.2.7 ENTEROME
    • 14.2.8 APSEN FARMACEUTICA
    • 14.2.9 METAGEN, INC.
    • 14.2.10 SNIPR BIOME
    • 14.2.11 MIKROBIOMIK
    • 14.2.12 SYNLOGIC
    • 14.2.13 GENETIC ANALYSIS
    • 14.2.14 METABIOMICS
    • 14.2.15 SUN GENOMICS, INC.

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS